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Background and purpose   The defect that results after curettage 
of a bone tumor is usually filled in the same way. We report the 
outcome in patients with benign bone tumors that were treated 
with curettage but no filling.
Patients and methods   We retrospectively studied 78 patients 
(mean age at the time of operation was 27 (6–73) years, 44 men) 
who had had a benign bone tumor curetted with no filling of the 
defect.  The  commonest  tumor  types  were  giant  cell  tumor  of 
bone (27), fibrous dysplasia (13), enchondroma (9), and simple 
bone cyst (7). The mean size of the lesions was 35 (2–196) cm3. 
Normal activities, including full weight bearing for lower extrem-
ity lesions, were allowed after 3 months or less. The patients were 
followed for an average of 10 (1.2–21) years.
Results   A postoperative fracture with a minor displacement 
occurred in 3 patients, in 2 of them because of local recurrence. 
All fractures healed. Local recurrence occurred in 9 patients; 7 
of them had a giant cell tumor. Repeated local recurrences neces-
sitated above-knee amputation in 1 patient. All other patients had 
unrestricted activities of daily living.
Interpretation   Routine filling of curetted bone lesions does not 
appear to be necessary from a mechanical point of view.   

Benign bone tumors are often treated with intralesional curet-
tage, which creates a bone defect. To fill the defect, autogenous 
bone (Bickels et al. 1999), polymethylmethacrylate cement 
(Campanacci et al. 1990, Bini et al. 1995, Wada et al. 2002, 
Kivioja et al 2008), hydroxyapatite (Matsumine et al. 2004), 
and tricalcium phosphate (Hirata et al. 2006) are often used. 
The reason for filling the defect seems to be to increase final 
bone strength and, especially for giant cell tumors, to reduce 
the risk of local recurrence.
Enchondroma in the hand or foot can be successfully treated 
without filling (Hasselgren et al. 1991, Goto et al. 2002, 2004), 
however. Chigira et al. (1992) curetted benign bone tumors in 
different locations without filling and, even in large defects, 
they found bone remodeling with sufficient strength for daily 
activity. Waldram and Sneath (1989) stated that bone graft-
ing is not necessarily required after curettage of a giant cell 
tumor. Otherwise, few reports regarding this procedure have 
been published.
We retrospectively examined the outcome in patients with a 
benign bone tumor treated with curettage without filling.
Patients and methods
Patients
We retrospectively reviewed patients treated between 1987 
and 2007. The inclusion criteria were histologically confirmed 
benign bone tumors (except for tumors in the hands or feet) 
treated with curettage without any type of filling, and a mini-
mum of 1 year of follow-up. Patients who received adjuvant 
chemotherapy or radiotherapy were excluded (they had metas-
tasizing giant cell tumors).
78 patients (44 males) met the criteria for inclusion. Their 
mean age at the time of the operation was 27 (6–73) years. 
The mean follow-up period was 10 (1.2–21) years. The sites 
of the lesions were femur (33), lower leg bones (25), fore-
arm bones (7), pelvic bones (6), humerus (6), and clavicle (1). 
The diagnoses were giant cell tumors of bone (27), fibrous 
dysplasia (13), enchondroma (9), simple bone cyst (7), non-
ossifying fibroma (6), chondroblastoma (5), chondromyxoid 
fibroma  (4),  xanthofibroma  (3),  desmoplastic  fibroma  (2), 
benign fibrous histiocytoma (1), and osteofibrous dysplasia 10  Acta Orthopaedica 2009; 80 (1): 9–13
(1). Of the 27 giant cell tumors, 6 were radiographic grade-I 
lesions, 10 were grade-II, and 11 were grade-III, according to 
Campanacci et al. (1987). The lesion in 16 of the 78 patients 
was located within 15 mm of the surface of a weight-bearin-
joint: hip, knee, or ankle. 
The volume of defects was calculated as: width/2 × depth/2 
× height × π for defects of cylindrical form and width/2 × 
depth/2 × height/2 × 4/3π for spherical defects (Hirn et al. 
2008). The mean volume of the tumors was 35 (2–196) cm3. 
10 patients had a preoperative fracture (bone cyst (3), giant 
cell  tumor  (2),  fibrous  dysplasia  (2),  chondroblastoma  (1), 
desmoplastic fibroma (1), osteofibrous dysplasia (1)). Their 
lesions had a mean size of 48 (2–196) cm3 (unpaired t-test, p 
= 0.2 compared to lesions without fracture).
Operative technique and rehabilitation
A cortical fenestration sufficiently large to be able to visu-
alize the whole tumor cavity was made with an osteotome. 
The tumor was removed with curettes followed by enlarge-
ment of the cavity with a high-speed burr. The cavity was irri-
gated with sterile saline and was not filled in. All patients were 
allowed to begin range-of-motion exercises immediately after 
the operation. Orthoses for extremities were used for not more 
than 3 months. Patients with a lesion on the femur or tibia used 
no weight or partial weight for not more than 3 months after 
the operation. Patients with a pelvic lesion were allowed par-
tial weight bearing using a walking frame or crutches 3 weeks 
postoperatively. Plain radiographs were taken postoperatively 
and then every 3 months for 2 years. MRI or CT examinations 
were made at 6- or 12-month intervals to evaluate bone forma-
tion and detect local recurrence for 2 years.
Results
None  of  the  patients  developed  a  postoperative  infection. 
The lesions began to show bone formation on radiographs at 
3 months: the thickness of the cavity wall increased and the 
cavity gradually became radiopaque, although complete bone 
filling of all cavities was not achieved (Figures 1 and 2).
A postoperative fracture with a minor displacement occurred 
in 3 patients: 1 giant cell tumor, 1 osteofibrous dysplasia, and 
1 fibrous cortical defect. The giant cell tumor was a 31-cm3 
grade-III  lesion  in  the  distal  femur,  which  fractured  at  10 
months after the operation. A local recurrence was revealed 
by MR. Repeated local recurrences finally required an ampu-
tation. The osteofibrous dysplasia was a 13-cm3 lesion in the 
tibia. A fracture through a local recurrence occurred 12 months 
after  the  operation.  The  fracture  healed  with  closed  treat-
ment, after which curettage was performed The diagnosis was 
fibrous dysplasia at the first operation but it was changed to 
osteofibrous dysplasia after the second, which means that the 
patient should probably not have been operated (Campanacci 
and Laus 1981). The fibrous cortical defect was a 3-cm3 lesion 
of  the  fibula  and  the  operation  was  performed  because  of 
severe pain and strong anxiety of the patient concerning the 
disease. The patient was allowed to bear full weight just after 
the operation and had a fracture 3 weeks later, which healed 
without treatment. 
Local recurrence occurred in 9 patients, 7 of whom had 
a giant cell tumor (altogether, 27 patients had a giant cell 
tumor); another had a simple bone cyst and one had an osteo-
fibrous dysplasia. The mean time to recurrence was 22 (5–47) 
months. Local recurrence occurred in 1 of 6 grade-I giant cell 
tumors, in 1 of 10 grade-II, and in 5 of 11 grade-III tumors. 
Of the 9 patients with local recurrence, 1 patient with a giant 
cell tumor (of grade III) eventually required an amputation 
above the knee after repeated local recurrences. 1 patient with 
a giant cell tumor (grade III) of the proximal humerus had an 
en bloc resection and an intramedullary rod was secured into 
the remaining humerus and fastened proximally to a clavicle 
as a functional spacer (Kaelin and Emans 1985). 1 patient with 
a bone cyst was treated with injection of steroid into the cyst, 
and the other 6 patients underwent re-curettage without bone 
grafts. All of the patients were disease-free at the latest follow-
up.
At the latest follow-up, the patient who had been amputated 
above the knee after repeated recurrences of giant cell tumor 
needed a prosthesis. All other patients had unrestricted activi-
ties of daily living. There was only 1 case with degenerative 
changes in the joint adjacent to the lesion. This was a giant cell 
tumor of the tibia with 4 local recurrences.
Discussion
Many authors recommend that after curettage of benign bone 
tumors the defect should be filled with bone grafts or substi-
tutes such as cement, hydroxyapatite, or tricalcium phosphate. 
However, the necessity and risk of using such materials are 
poorly documented. Autogenous bone grafting has the advan-
tages of there being no immunological reaction and good bone 
induction, but sufficient bone for large defects may be difficult 
to obtain and may give sequelae at the donor site. Packing 
of defects with methylmethacrylate cement gives immediate 
stability, especially for lesions close to a joint (Frassica et al. 
1990). The thermal effects of cement polymerization induce 
some millimeters of bone necrosis, which may kill residual 
tumor cells (Mjöberg et al. 1984)—but this has also been sus-
pected of damaging cartilage and subchondral bone in lesions 
close to a joint, which may be followed by degenerative arthri-
tis (Campanacci et al. 1990, Bini et al. 1995). However, a recent 
long-term follow-up study of cemented giant cell tumors did 
not show that there was a high risk of osteoarthritis develop-
ment (Vult von Steyern et al. 2007). Hydroxyapatite has been 
used to fill cavities after curettage (Itokazu et al. 1996, Mat-
sumine et al. 2004) but it may interact with human monocytes, 
leading to the release of inflammatory cytokines (Laquerriere Acta Orthopaedica 2009; 80 (1): 9–13  11
Figure 2. A 32-year-old female with fibrous dysplasia in the sacrum. 
More than half of the sacral body was occupied by the tumor, which 
invaded the sacral canal to a slight degree. Computed tomography 
showed good bone formation of the curetted wall 1 year after the oper-
ation.
Figure 1. A 34-year-old male with a giant cell tumor in the left femur. A. Computed tomography showed a thin wall around the cavity 1 month after 
the curettage. B. 1 year postoperatively, bone formation was excellent and the cortex of the cavity was thicker than the normal cortex of the medial 
condyle.
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et al. 2003, Grandjean-Laquerriere et al. 2007). Successful 
filling of bone defects with β-tricalcium phosphate has been 
reported by Hirata et al. (2006). However, tibial cyst formation 
has been reported in an anterior cruciate ligament reconstruc-
tion using a bioabsorbable screw made of β-tricalcium phos-
phate and poly L-lactide (Malhan et al. 2002). Grafting with 
hydroxyapatite (Hamson et al. 1995, Matsumine et al. 2004) 
or β-tricalcium phosphate (Hirata et al. 2006) requires several 
months for bone incorporation. Only cement filling gives a 
degree of mechanical strength that is sufficient for immediate 
weight bearing. The lack of difference in required convales-
cence time between grafting with biodegradable materials and 
leaving the cavity empty compelled us to question the practice 
of filling the cavity with substitutes that may evoke foreign 
body reactions. 
We found that curettage without filling of the defect led to 
a degree of bone strength that was sufficient for the activities 
of daily living in the majority of patients. We did not try to 
measure the amount of bone formation and remodeling; the 12  Acta Orthopaedica 2009; 80 (1): 9–13
exact radiographic appearance is of minor interest, as long as 
the strength of the bone permits normal activities. A postop-
erative fracture with minor displacement occurred in 3 cases; 
1 of them could probably have been prevented with limitation 
of postoperative weight bearing, and the 2 others occurred in 
local recurrences. 
In our series, local recurrence occurred in only 2 of the 51 
tumors that were not giant cell tumors. 9 local recurrences 
occurred in the 27 giant cell tumors, however, 5 of them in 11 
radiographic grade-III tumors. To prevent local recurrence of 
giant cell tumors, adjuvant therapies may be used after curet-
tage. Filling of the cavity with bone cement gives immediate 
mechanical strength and is also thought to kill residual tumor 
cells by the heat generated during the polymerization, thereby 
reducing the local recurrence rate. However, the recurrence 
rate after cementation ranges from excellent to equivalent to 
that after curettage without cement (O’Donnell et al. 1994, 
Turcotte et al. 2002, Vult von Steyern et al. 2006, Kivioja et 
al. 2008). The necrotic effect of cement on the local recur-
rence rate seems to be unclear. Liquid nitrogen has been used 
as  an  adjuvant  treatment  for  giant  cell  tumors  after  curet-
tage because of its ability to induce osteonecrosis to a depth 
of 7–12 mm (Malawer et al. 1988). This treatment has been 
reported to reduce the local recurrence rate; however, the rate 
of postoperative fractures is high due to difficulty in control-
ling the amount of necrosis induced (Jacobs and Clemency 
1985, Bickels et al. 1999, Malawer et al. 1999). Phenol has 
also been used to kill residual tumor cells after curettage of 
giant cell tumors, but the recurrence rates have been reported 
to  show  no  improvement  (McDonald  et  al.  1986, Turcotte 
et al. 2002). Extensive curettage of the tumor may be more 
important than the use of adjuvant therapies (Blackley et al. 
1999, Eckardt and Grogan 1986).
In summary, we consider curettage without filling of the 
defect to be a standard treatment for benign bone tumors. 
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